CommercializationXOLREMDI sales increased significantly, surpassing estimates, due to commercialization progress and inventory build.
EarningsThe company reported total revenue of $28.8M, compared to the consensus estimate of $11.6M, and a net income of $0.04 per share, compared to the consensus estimated a net loss of $0.12 per share.
Licensing AgreementX4 is expected to receive an initial upfront payment of €28.5M and up to €226M in regulatory, commercial, and sales milestones from the agreement with Norgine.